Jurors at the trial, according to a report in Bloomberg News (8/15/13), were told by plaintiff lawyers that Bard continued with production.
Plaintiff Donna Cisson and the events fostering her Avaulta lawsuit appears to be a fair representation of what other plaintiffs are alleging in thousands of additional lawsuits currently in the pipeline.
Cisson, a public health nurse, received her Bard Avaulta in 2009 in an effort to treat POP. The latter is a condition often affecting women at midlife or later - and especially women who have borne children - when organs begin to sag and collapse into the pelvic region. The use of surgical mesh, such as Bard Avaulta mesh, to shore up migrating organs in a sling-like fashion has replaced traditional procedures that involved more invasive surgery to stitch a patient’s own tissue, harvested from elsewhere, into a sling.
Cisson’s implant, however, proved problematic. The plaintiff required several surgical procedures to remove the mesh after Cisson began encountering bladder spasms, pain and bleeding.
Other plaintiffs have alleged similar complaints, including but not limited to uterine perforation and pain during sexual intercourse for both partners.
In 2012, a state jury in California found for the plaintiff in a case that was the first to go to trial in US court, according to Bloomberg News. Jurors awarded the plaintiff $5.5 million, although Bard is described as only having to pay $3.6 million of the award according to state laws in California.
READ MORE BARD AVAULTA TVM LEGAL NEWS
Bard is one of over 30 manufacturers of mesh implants ordered by the FDA to study rates of injury, complication and adverse reaction post-market. Jurors in the Cisson case deliberated for 12 hours over two days before delivering the verdict for the plaintiff in federal court in Charleston, West Virginia. Another trial alleging injury stemming from the Bard Avaulta mesh implant - in this case, the Avaulta Plus - was scheduled to go to trial also in West Virginia this month.